Haemonetics FY2026 EPS Forecast Raised by Zacks Research

Haemonetics Corporation (NYSE:HAE) – Investment analysts at Zacks Research lifted their FY2026 earnings estimates for Haemonetics in a report issued on Tuesday, February 24th. Zacks Research analyst Team now forecasts that the medical instruments supplier will post earnings of $4.95 per share for the year, up from their previous estimate of $4.93. The consensus estimate for Haemonetics’ current full-year earnings is $4.55 per share. Zacks Research also issued estimates for Haemonetics’ Q4 2026 earnings at $1.27 EPS, Q2 2027 earnings at $1.37 EPS, Q4 2027 earnings at $1.37 EPS, FY2027 earnings at $5.34 EPS, Q2 2028 earnings at $1.46 EPS and Q3 2028 earnings at $1.51 EPS.

Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.27 by $0.04. The company had revenue of $338.97 million for the quarter, compared to analysts’ expectations of $331.90 million. Haemonetics had a return on equity of 27.32% and a net margin of 13.31%.The firm’s revenue for the quarter was down 2.7% on a year-over-year basis. During the same period in the previous year, the firm posted $1.19 earnings per share. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS.

HAE has been the topic of several other research reports. Citigroup reduced their price target on shares of Haemonetics from $88.00 to $75.00 and set a “neutral” rating on the stock in a research note on Friday, February 6th. Needham & Company LLC lowered Haemonetics from a “buy” rating to a “hold” rating in a report on Monday, December 15th. Robert W. Baird set a $81.00 price objective on Haemonetics in a research note on Friday, February 6th. BTIG Research restated a “buy” rating and set a $88.00 price objective on shares of Haemonetics in a report on Friday, February 6th. Finally, Raymond James Financial reaffirmed an “outperform” rating and set a $90.00 target price on shares of Haemonetics in a research report on Friday, November 14th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $84.44.

Haemonetics Stock Performance

NYSE HAE opened at $62.21 on Wednesday. The business’s 50 day moving average price is $70.47 and its 200-day moving average price is $63.96. Haemonetics has a fifty-two week low of $47.31 and a fifty-two week high of $87.32. The company has a market cap of $2.89 billion, a P/E ratio of 17.14, a P/E/G ratio of 1.30 and a beta of 0.28. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.15 and a current ratio of 1.75.

Hedge Funds Weigh In On Haemonetics

Hedge funds have recently modified their holdings of the stock. Kemnay Advisory Services Inc. purchased a new position in shares of Haemonetics in the fourth quarter worth $26,000. True Wealth Design LLC grew its position in shares of Haemonetics by 6,700.0% in the fourth quarter. True Wealth Design LLC now owns 340 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 335 shares during the period. Leonteq Securities AG acquired a new position in Haemonetics in the 4th quarter valued at $30,000. EverSource Wealth Advisors LLC lifted its stake in Haemonetics by 2,640.0% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 396 shares in the last quarter. Finally, Kestra Advisory Services LLC purchased a new stake in shares of Haemonetics in the fourth quarter valued at about $34,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

More Haemonetics News

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Zacks nudged FY2026 EPS slightly higher to $4.95 (from $4.93), and raised its Q2 2027 estimate to $1.37 (from $1.35) — small upside near‑term beats that may cushion downside from other cuts. Zacks estimate updates (Feb 24)
• Neutral Sentiment: Zacks published a comprehensive set of updated quarterly and fiscal estimates (Q4 2026 – Q3 2028 and FY2026–FY2028), providing a refreshed model investors can use to re‑rate the stock. Zacks estimate updates (Feb 24)
• Negative Sentiment: Material downward revisions to the medium/longer term: Zacks cut FY2028 EPS to $5.73 from $5.90 and trimmed FY2027 to $5.34 from $5.37 — signaling lower expected growth beyond FY2026. Zacks estimate updates (Feb 24)
• Negative Sentiment: Zacks lowered multiple quarterly forecasts across 2026–2028 (examples: Q1 2028 to $1.35 from $1.39; Q1 2027 to $1.19 from $1.20; Q3 2028 to $1.51 from $1.53; Q2 2028 to $1.46 from $1.50; Q4 2027 and Q4 2026 also trimmed). These repeated downgrades put near‑term EPS risk on the table. Zacks estimate updates (Feb 24–25)

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.